Screening/Prevention
September Is National Leukemia and Lymphoma Awareness Month
(09/02/2008)
As the month of September brings leukemia and lymphoma into focus, it’s a great time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Cyclophosphamide May Increase Cancer Risk Among Patients with Rheumatoid Arthritis
(03/10/2008)
A large study conducted in Canada reveals that patients who are treated for rheumatoid arthritis (RA) with the drug cyclophosphamide may have an increased risk for developing hematological cancers such as lymphoma.
Being Overweight Associated with Increased Risk of Several Cancers
(02/19/2008)
Excess bodyweight increases the risk of developing several types of cancer, according to results recently published in The Lancet.
Hepatitis C Virus May Increase Risk of Non-Hodgkin’s Lymphoma
(05/10/2007)
According to the results of a study published in the Journal of the American Medical Association, individuals who are infected with the hepatitis C virus are 20–30% more likely than non-infected individuals to develop non-Hodgkin’s lymphoma.
No Clear Link Between Allergy and Non-Hodgkin’s Lymphoma
(01/17/2007)
According to the results of studies conducted in Denmark, Sweden, and Finland, allergy does not appear to influence the risk of developing non-Hodgkin’s lymphoma. These results were published in the Journal of the National Cancer Institute.
More...
Indolent/Low Grade
September Is National Leukemia and Lymphoma Awareness Month
(09/02/2008)
As the month of September brings leukemia and lymphoma into focus, it’s a great time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Maintenance Rituxan® Is Cost-effective for Follicular Lymphoma
(08/26/2008)
Continued treatment (maintenance therapy) with Rituxan® (rituximab) appears to be cost-effective, as well as safe and effective, in the treatment of follicular lymphoma, a form of low-grade non-Hodgkin’s lymphoma. These results were recently published in the journal Clinical Lymphoma Myeloma.
BiovaxID® Improves Disease-free Survival in Non-Hodgkin’s Lymphoma
(07/21/2008)
The personalized investigative vaccine BiovaxID® (personalized anti-idiotype vaccine) significantly improves cancer-free survival among patients with non-Hodgkin’s lymphoma. These results were released in a press release by Accentia BioPharmaceuticals.
Treanda® plus Rituxan® Effective for Recurrent Non-Hodgkin’s Lymphoma
(07/15/2008)
The treatment combination consisting of Treanda® (bendamustine) plus Rituxan® (rituximab) provides effective therapy for patients with non-Hodgkin’s lymphoma (NHL) that has stopped responding to prior treatment. These results were recently published in the Journal of Clinical Oncology.
Maintenance Rituxan® Is Safe for Follicular Lymphoma
(07/03/2008)
Continued treatment for up to two years with Rituxan® (rituximab) is a safe therapeutic approach for the treatment of follicular lymphoma. These results were recently presented at the 2008 annual meeting of the American Society of Clinical Oncology.
More...
Highly Aggressive/High Grade
September Is National Leukemia and Lymphoma Awareness Month
(09/02/2008)
As the month of September brings leukemia and lymphoma into focus, it’s a great time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Smoking and Heavy Alcohol Consumption Reduce Survival in Non-Hodgkin's Lymphoma
(05/13/2008)
Patients diagnosed with non-Hodgkin’s lymphoma (NHL) who smoke tobacco products and/or drink large quantities of alcohol have a reduced chance of optimal survival. These results were recently published in the International Journal of Cancer.
Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma
(04/01/2008)
Statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL), according to a recently published article in PLoS Med (the Public Library of Science journal).
Non-Hodgkin’s Lymphoma Survivors May Suffer Symptoms of Post Traumatic Stress
(02/26/2008)
Patients who have been diagnosed and treated for non-Hodgkin’s lymphoma may have symptoms of post traumatic stress disorder (PTSD). These finding were recently published in the Journal of Clinical Oncology.
Tobacco and Alcohol May Decrease Survival for Non-Hodgkin’s Lymphoma Patients
(02/11/2008)
Heavy tobacco smoking and alcohol consumption may be associated with poor survival among patients with Non-Hodgkin’s Lymphoma (NHL). These findings were recently reported in the International Journal of Cancer.
More...
Mantle Cell
September Is National Leukemia and Lymphoma Awareness Month
(09/02/2008)
As the month of September brings leukemia and lymphoma into focus, it’s a great time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma
(04/01/2008)
Statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL), according to a recently published article in PLoS Med (the Public Library of Science journal).
Non-Hodgkin’s Lymphoma Survivors May Suffer Symptoms of Post Traumatic Stress
(02/26/2008)
Patients who have been diagnosed and treated for non-Hodgkin’s lymphoma may have symptoms of post traumatic stress disorder (PTSD). These finding were recently published in the Journal of Clinical Oncology.
Long-term Quality-of-life Issues Persist Among Non-Hodgkin’s Lymphoma Survivors
(04/11/2007)
According to an article recently published in the journal Cancer, long-term survivors of non-Hodgkin’s lymphoma have quality-of-life concerns that deserve attention following treatment.
Velcade® Effective in Mantle Cell Lymphoma
(10/26/2006)
According to an article recently published in the Journal of Clinical Oncology, Velcade® (bortezomib) is an effective treatment option for patients with mantle cell lymphoma that has stopped responding to prior therapies.
More...
T-Cell
September Is National Leukemia and Lymphoma Awareness Month
(09/02/2008)
As the month of September brings leukemia and lymphoma into focus, it’s a great time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma
(04/01/2008)
Statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL), according to a recently published article in PLoS Med (the Public Library of Science journal).
Long-term Quality-of-life Issues Persist Among Non-Hodgkin’s Lymphoma Survivors
(04/11/2007)
According to an article recently published in the journal Cancer, long-term survivors of non-Hodgkin’s lymphoma have quality-of-life concerns that deserve attention following treatment.
Interleukin-12 Shows Promise Against Mycosis Fungoides
(10/30/2006)
According to the results of a phase II clinical trial published in the Journal of the American Academy of Dermatology, interleukin-12 (IL-12) produces a treatment response in some patients with previously treated mycosis fungoides, a type of T-cell lymphoma.
Zolinza™ Approved for Cutaneous T-cell Lymphoma
(10/10/2006)
The United States Food and Drug Administration (FDA) has approved Zolinza™ (vorinostat) for the treatment of patients with cutaneous (skin) T-cell lymphoma that has stopped responding to at least two previous systemic (full body) therapies.
More...
Recurrent
September Is National Leukemia and Lymphoma Awareness Month
(09/02/2008)
As the month of September brings leukemia and lymphoma into focus, it’s a great time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Zevalin® Effective for Treatment of Cutaneous B-Cell Lymphoma
(08/25/2008)
Zevalin® (Yttrium-90 [(90)Y] ibritumomab tiuxetan) appears highly effective in the treatment of primary cutaneous B-cell lymphoma (PCBCL). The details of this study appeared in an early online publication in Leukemia-Lymphoma on July 25, 2008.
Zevalin® Effective for Patients with Follicular Lymphoma Following an Autologous Transplant
(08/25/2008)
Zevalin® (Yttrium-90 [(90)Y] ibritumomab tiuxetan) appears to provide effective, long-term anticancer responses for patients with follicular lymphoma whose cancer has progressed following an autologous stem cell transplant. The details of this small study appeared in an early online publication of Leukemia-Lymphoma of July 15, 2008.
Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma
(04/01/2008)
Statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL), according to a recently published article in PLoS Med (the Public Library of Science journal).
Stem Cell Transplant May Improve Survival Among Elderly with Relapsed Non-Hodgkin’s Lymphoma
(03/11/2008)
A recent study reveals that elderly patients with relapsed non-Hodgkin’s Lymphoma (NHL) may benefit from autologous stem cell transplant. Results from the study, conducted at the M.D. Anderson Cancer Center in Texas, were recently published in Annals of Oncology.
More...
Aggressive/Intermediate Grade
September Is National Leukemia and Lymphoma Awareness Month
(09/02/2008)
As the month of September brings leukemia and lymphoma into focus, it’s a great time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Zevalin® Effective for Treatment of Cutaneous B-Cell Lymphoma
(08/25/2008)
Zevalin® (Yttrium-90 [(90)Y] ibritumomab tiuxetan) appears highly effective in the treatment of primary cutaneous B-cell lymphoma (PCBCL). The details of this study appeared in an early online publication in Leukemia-Lymphoma on July 25, 2008.
Treanda® plus Rituxan® Effective for Recurrent Non-Hodgkin’s Lymphoma
(07/15/2008)
The treatment combination consisting of Treanda® (bendamustine) plus Rituxan® (rituximab) provides effective therapy for patients with non-Hodgkin’s lymphoma (NHL) that has stopped responding to prior treatment. These results were recently published in the Journal of Clinical Oncology.
Smoking and Heavy Alcohol Consumption Reduce Survival in Non-Hodgkin's Lymphoma
(05/13/2008)
Patients diagnosed with non-Hodgkin’s lymphoma (NHL) who smoke tobacco products and/or drink large quantities of alcohol have a reduced chance of optimal survival. These results were recently published in the International Journal of Cancer.
Worse Prognosis for “Bulky” Disease Diffuse Large B-Cell Lymphoma
(05/08/2008)
Young patients with diffuse large-B-cell lymphoma (DLBCL) with cancerous masses that are 10.0 centimeters or greater in diameter are considered to have “bulky” disease and have a worse prognosis than those with smaller masses. These findings were published in Lancet Oncology.
More...